Previous 10 | Next 10 |
TScan Therapeutics ( NASDAQ: TCRX ) has appointed Dr. Debora Barton, as Chief Medical Officer. Most recently, Dr. Barton was the Chief Medical Officer at Carisma Therapeutics. In May, TScan got FDA nod to start trial of TSC-101 in blood cancer patie...
WALTHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appoin...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
WALTHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that manag...
WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that manag...
TScan Therapeutics (NASDAQ:TCRX) said the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for starting a study of TSC-101 to treat patients with hematologic malignancies (blood cancers) who are undergoing allogeneic hematopoietic cell transplanta...
WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the U....
Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...
Identified lead TCR-T cell therapy candidate, TCR-200-A02, for the treatment of HPV-positive solid tumors, on track for IND submission in 2H22 TCR directed to a novel C*07:02-restricted epitope of MAGEA1, TSC-204-C07, on track for IND submission in 2H22 Multiplexing TCRs...
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that manage...
News, Short Squeeze, Breakout and More Instantly...
TScan Therapeutics Inc. Company Name:
TCRX Stock Symbol:
NYSE Market:
TScan Therapeutics Inc. Website:
2024-07-26 15:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-16 12:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-26 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...